Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction
Go back to Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction| Assisted Living Concepts, Inc. New (NYSE: ALC) | Delayed: 66.12 +0.94 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.18 | 52 Week High | $14.66 | |||
| Open | $65.98 | 52 Week Low | $6.93 | |||
| Day High | $66.67 | P/E | N/A | |||
| Day Low | $65.32 | EPS | $-1.75 | |||
| Volume | 2,291,954 | |||||
